×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Exchange
/
Drug Targets
🎯 Drug Targets
Browse 8 drug targets with druggability analysis, composite scores, and clinical context
8
Targets
2
High Druggability
0.64
Avg Score
15
Target Classes
Druggability Distribution
High:
2
Medium:
1
Low:
5
Unknown:
0
Avg druggability score:
0.500
Clinical Pipeline
Approved:
2
Phase III:
0
Phase II:
2
Phase I:
3
Preclinical:
1
Total compounds:
14
· Approved:
2
Search
Class
All Classes
Enzyme
(35)
Signaling Protein
(25)
Structural Protein
(17)
Protein
(16)
Gpcr
(13)
Ion Channel
(12)
Transcription Factor
(11)
Receptor
(11)
Ligand
(10)
Transporter
(8)
Epigenetic Regulator
(8)
Kinase
(7)
Protease
(4)
Other
(4)
Chaperone
(4)
Druggability
Low
(100)
Medium
(62)
High
(14)
Undruggable
(6)
other
(3)
Sort
Score
Druggability
Gene A-Z
Market Price
Filtered by: class=epigenetic_regulator — 8 results
BRD4
Bromodomain-containing protein 4
Epigenetic Regulator
High Druggability
Score
0.72
Drug.
0.73
Safety
0.62
Drugs
2
Hyps
1
Papers
35
BRD4 inhibition reduces neuroinflammatory super-enhancer activity while biased BRD4 modulators can selectively restore neuroprotective gene expression
HDAC3
Histone Deacetylase 3
Phase 4
Epigenetic Regulator
Low Druggability
Score
0.66
Drug.
0.41
Safety
0.40
Drugs
2
Hyps
5
Papers
36
Small molecule inhibitor of histone deacetylase enzymatic activity
SIRT6
Sirtuin-6
Phase 1
Epigenetic Regulator
Low Druggability
Score
0.65
Drug.
0.41
Safety
0.60
Drugs
1
Hyps
2
Papers
36
Small molecule activation or inhibition of NAD+-dependent deacetylase activity
DNMT1
DNA methyltransferase 1
Phase 4
Epigenetic Regulator
Medium Druggability
Score
0.64
Drug.
0.52
Safety
0.30
Drugs
2
Hyps
6
Papers
36
Small molecule inhibitor of DNA methyltransferase activity
SIRT1
NAD-dependent protein deacetylase sirtuin-1
Phase 2
Epigenetic Regulator
High Druggability
Score
0.63
Drug.
0.80
Safety
0.73
Drugs
3
Hyps
2
Papers
44
SIRT1 activation via NAD+ precursors or allosteric activators deacetylates tau (reducing aggregation), enhances mitophagy, and restores circadian gene expression
TET2
Tet methylcytosine dioxygenase 2
Phase 2
Epigenetic Regulator
Low Druggability
Score
0.61
Drug.
0.42
Safety
0.60
Drugs
2
Hyps
6
Papers
65
Small molecule enhancers of TET2 enzymatic activity or cofactor supplementation
PRMT1
Protein arginine methyltransferase 1
Phase 1
Epigenetic Regulator
Low Druggability
Score
0.61
Drug.
0.36
Safety
0.50
Drugs
1
Hyps
1
Papers
32
Small molecule inhibitor of protein arginine methyltransferase activity
KDM6A
Lysine demethylase 6A
Phase 1
Epigenetic Regulator
Low Druggability
Score
0.59
Drug.
0.35
Safety
0.40
Drugs
1
Hyps
1
Papers
36
Small molecule inhibition of histone demethylase activity